Is Phytalgic® a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Christensen, Robin ^a,b   Bliddal, Henning ^a,c  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; FISH OIL; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; PHYTALGIC; PLACEBO; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; ZINC;

CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG EFFECT; EDITORIAL; HUMAN; OSTEOARTHRITIS; EPIDEMIOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; URTICA DIOICA;

BIAS (EPIDEMIOLOGY); DIETARY SUPPLEMENTS; FISH OILS; HUMANS; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URTICA DIOICA; VITAMIN E; ZINC;

EID: 77955490456     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2909     Document Type: Editorial

References (12)

1. Jacquet A, Girodet PO, Pariente A, Forest K, Mallet L, Moore N. Phytalgic(R) a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial. Arthritis Res Ther 2009, 11:R192. 10.1186/ar2891, 20015358.
2. ClinicalTrials.gov homepage. , http://clinicaltrials.gov
3. Bliddal H, Christensen R. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making. Expert Opin Pharmacother 2009, 10:1793-1804. 10.1517/14656560903018911, 19537998.
4. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000. 10.1016/j.joca.2007.06.014, 17719803.
5. Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, Christensen K, Jensen ON, Barslev J. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000, 8:9-12. 10.1053/joca.1999.0264, 10607493.
6. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008, 16:399-408. 10.1016/j.joca.2007.10.003, 18042410.
7. Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? - a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008, 16:965-972. 10.1016/j.joca.2008.03.001, 18407528.
8. Bartels EM, Bliddal H, Schondorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2009,
9. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 2007, 56:2267-2277. 10.1002/art.22728, 17599746.
10. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007, 56:2105-2110. 10.1002/art.22852, 17599727.
11. Nuesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, Altman DG, Juni P. The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum 2009, 61:1633-1641. 10.1002/art.24894, 19950329.
12. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M, Altman DG, Juni P. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ 2009, 339:b3244. 2739282, 19736281, 10.1136/bmj.b3244.